Introduction
============

Reducing levels of modifiable cardiovascular risk factors is a key goal in the prevention of cardiovascular diseases (CVD), and guidelines are an important means of achieving this goal ([@b19]). Primary preventive treatment is targeted at patients who are asymptomatic but are at elevated absolute 10-year CVD risk. Identification of persons at high risk is guided by so-called risk tables, which are tools designed for the assessment of an individual's risk score. Numerous CVD-risk tables are available ([@b39]; [@b51]). Risk tables differ in many respects, eg, in the way risks are framed and presented, the number of risk factors included, outcome measures, interpretation, and indications for medical treatment ([@b43]; [@b3]; [@b39]). These differences, and the validity of the prediction function, are still subjects of study and debate ([@b1]; [@b19]; [@b50]).

Despite certain weaknesses or restrictions, there is no doubt about the value of risk tables for preventive treatment in everyday patient care. However, extensive efforts to publish and disseminate such tables have not yet resulted in the desired level of implementation in routine practice ([@b4]). A systematic review of the effectiveness of cardiovascular risk tables as regards risk reduction in daily practice was inconclusive in terms of the effect on patients' risk reduction, because application of the risk tables by the professionals was not optimal. It became clear that a serious implementation problem needed to be addressed. The poor uptake of risk tables by the physicians was confirmed in observational studies ([@b1]). A risk calculator for risk management was only routinely used by 17% of American family physicians ([@b7]), and less than half of the physicians in two European studies ([@b5]; [@b19]). Moreover, Australian GPs reported that -- if they used cardiovascular risk assessment tools at all -- they used them in a restricted manner, only as an aid to patient education ([@b45]). Apparently, there is a gap between the high risk approach advocated in the prevention of CVD and the actual use of risk tables in routine practice. A high-risk approach supported by risk tables seems to be an innovation that is not easy to implement. It is important to investigate what implementation strategies are most effective to ensure a good uptake of the risk tables in normal practice.

The literature reports on many different methods, strategies, and measures to introduce innovations, guidelines, best practices, or new procedures into clinical practice ([@b20]). Effective implementation of innovations seems to be more successful with strategies for implementation that are tailored to the specific goals, target group and setting ([@b21], [@b22], [@b23]; [@b38]). Therefore, the objective of our study was to systematically review the literature on health professionals' performance with respect to cardiovascular risk tables, in order to search for implementation strategies that enable professionals to use cardiovascular risk tables effectively in the prevention of CVD.

Methods
=======

Design
------

Systematic literature review.

Studies included
----------------

A study was eligible for inclusion in the review if it met the following inclusion criteria:

-   quantitative empirical data were reported;

-   a professional, financial, organizational, or regulatory strategy was used to implement a CVD-risk table ([Table 1](#tbl1){ref-type="table"});

-   participants were physicians or nurses;

-   the primary outcome measure was professionals' performance regarding the actual use of cardiovascular risk tables, and the secondary outcome measure was patients' cardiovascular risk reduction by improving one or more modifiable risk factors, eg, blood pressure, cholesterol, smoking, etc.

No restrictions were used as regards setting.

###### 

Types of intervention, listed according to EPOC[a](#tf1-1){ref-type="table-fn"}

  Professional interventions              Financial interventions        Organizational interventions                                                                              Regulatory interventions
  --------------------------------------- ------------------------------ --------------------------------------------------------------------------------------------------------- ----------------------------------
  Distribution of educational materials   Provider interventions         Provider oriented interventions                                                                           Changes in medical liability
  Educational meetings.                    Fee-for-service                Revision of professional roles                                                                           Management of patient complaints
  Local consensus processes                Prepaid                        Clinical multidisciplinary teams                                                                         Peer review
  Educational outreach visits              Capitation                     Formal integration of services                                                                           Licensure
  Local opinion leaders                    Provider salaried service      Skill mix changes                                                                                        
  Patient-mediated interventions           Prospective payment            Continuity of care                                                                                       
  Audit and feedback                       Provider incentives             Arrangements for follow-up                                                                              
  (Computerized) reminders                 Institution incentives          Case management (including co-ordination of assessment, treatment and arrangements for referrals).      
  Marketing                                Provider grant/allowance       Satisfaction of providers with the conditions of work and the material and psychological rewards         
  Mass media                               Institution grant/allowance    Communication and case discussion between distant health professionals                                   
                                           Provider penalty              Patient oriented interventions                                                                            
                                           Institution penalty            Mail order pharmacies                                                                                    
                                           Formulary                      Presence and functioning of adequate mechanisms for dealing with patients' suggestions and complaints.   
                                          Patient interventions           Consumer participation in governance of health care organizations                                        
                                           Premium                       Structural interventions                                                                                  
                                           Co-payment                     Changes to the setting/site of service delivery                                                          
                                           User-free                      Changes in physical structure, facilities and equipment                                                  
                                           Patient incentives             Changes in medical record systems                                                                        
                                           Patient grant/allowance        Changes in scope and nature of benefits and services.                                                    
                                           Patient penalty                Presence and organization of quality monitoring mechanisms.                                              
                                                                          Ownership, accreditation, and affiliation status of hospitals and other facilities.                      
                                                                         Staff organization                                                                                        

**Notes:** Other categories to be agreed in consultation with the EPOC editorial team.

Search strategy
---------------

We elaborated on the extensive search strategy used by [@b1], who recently reviewed the accuracy and impact of risk assessment in the primary prevention of CVD. We added free-text search terms related to the implementation of cardiovascular risk tables. [Table 2](#tbl2){ref-type="table"} details the terms used to search MEDLINE. Appropriate adaptations of the search syntax were made when searching EMBASE, CINAHL, and PSYCHINFO. We covered the period from database inception to February 2007. Reference lists of included articles were scanned to identify additional study reports. Languages were restricted to Dutch, English, and German.

###### 

Medline search terms and strategy

  Basic search strategy (Brindle)                                                                   
  ------------------------------------------------ ------------------------------------------------ -----------------------------------------------
  \#1 chd risk assessment\$                        \#37 risk calculation\$                          \#72 (busselton adj2 score\$)
  \#2 cvd risk assessment\$                        \#38 risk calculator\$                           \#73 erica risk score\$
  \#3 heart disease risk assessment\$              \#39 risk factor\$ calculator\$                  \#74 framingham scor\$
  \#4 coronary disease risk assessment\$           \#40 risk factor\$ calculation\$                 \#75 dundee scor\$
  \#5 cardiovascular disease risk assessment\$     \#41 risk engine\$                               \#76 brhs scor\$
  \#6 cardiovascular risk assessment\$             \#42 risk equation\$                             \#77 British Regional Heart study risk scor\$
  \#7 cv risk assessment\$                         \#43 risk table\$                                \#78 brhs risk scor\$
  \#8 cardiovascular disease\$ risk assessment\$   \#44 risk threshold\$                            \#79 dundee risk scor\$
  \#9 coronary risk assessment\$                   \#45 risk disc?                                  \#80 framingham guideline\$
  \#10 coronary risk scor\$                        \#46 risk disk?                                  \#81 framingham risk?
  \#11 heart disease risk scor\$                   \#47 risk scoring method?                        \#82 new zealand table\$
  \#12 chd risk scor\$                             \#48 scoring scheme?                             \#83 ncep guideline?
  \#13 cardiovascular risk scor\$                  \#49 risk scoring system?                        \#84 smac guideline?
  \#14 cardiovascular disease\$ risk scor\$        \#50 risk prediction?                            \#85 copenhagen risk?
  \#15 cvd risk scor\$                             \#51 predictive instrument?                      **\#86 or/57--85**
  \#16 cv risk scor\$                              \#52 project\$ risk?                             **\#87 56 or 86**
  **\#17 or/1--16**                                \#53 cdss                                        \#88 exp decision support techniques/
  \#18 cardiovascular diseases/                    **\#54 or/28--53**                               \#89 Diagnosis, Computer-Assisted/
  \#19 coronary disease/                           **\#55 27 and 54**                               \#90 Decision Support Systems, Clinical/
  \#20 cardiovascular disease\$                    **\#56 17 or 55**                                \#91 algorithms/
  \#21 heart disease\$                             \#57 new zealand chart\$                         \#92 algorithm?
  \#22 coronary disease\$                          \#58 sheffield table\$                           \#93 algorythm?
  \#23 cardiovascular risk?                        \#59 procam                                      \#94 decision support?
  \#24 coronary risk?                              \#60 General Rule to Enable Atheroma Treatment   \#95 predictive model?
  \#25 exp hypertension/                           \#61 dundee guideline\$                          \#96 treatment decision?
  \#26 exp hyperlipidemia/                         \#62 shaper scor\$                               \#97 scoring method\$
  **\#27 or/18--26**                               \#63 (brhs adj3 score\$)                         \#98 (prediction\$ adj3 method\$)
  \#28 risk function                               \#64 (brhs adj3 risk\$)                          **\#99 or/88--98**
  \#29 Risk Assessment/mt (Methods)                \#65 copenhagen risk                             \#100 Risk Factors/
  \#30 risk functions                              \#66 precard                                     \#101 exp Risk Assessment/
  \#31 risk equation\$                             \#67 (framingham adj1 (function or functions))   \#102 (risk? adj1 assess\$)
  \#32 risk chart?                                 \#68 (framingham adj2 risk)                      \#103 risk factor?
  \#33 (risk adj3 tool\$)                          \#69 framingham equation                         **\#104 or/100--103**
  \#34 risk assessment function?                   \#70 framingham model\$                          **\#105 27 and 99 and 104**
  \#35 risk assessor                               \#71 (busselton adj2 risk\$)                     **\#106 87 or 105 (448.950)**
  \#36 risk appraisal\$                                                                             
  **Adjustments for the current review**                                                            
  \#107 106 and quality\* health care              \#116 115 and clin\* trial                       **\#129 128 and cardio\* risk\***
  \#108 106 and practice pattern\* health care     \#117 115 and rand\* trial                       **\#130 128 and risk tables**
  \#109 106 and implement\* strateg\*              \#118 115 and randomised trial                   **\#131 128 and cardio\* risk?**
  \#110 106 and implement\*                        \#119 115 and randomized trial                   **\#132 128 and risk manag\***
  \#111 106 and dissemination                      \#120 115 and clinical trial                     
  \#112 106 and diffus\*                           \#121 115 and cohort                             **\#133 115 and process assessment**
  \#113 106 and guideline\*                        \#121 115 and control\* trial                    **\#134 115 and process evaluation**
  \#114 106 and implementation?                    \#122 115 and comparat\* study                   **\#135 115 and \#17**
  **\#115 107--114 (18607)**                       \#123 115 and random\* control\* trial           
                                                   \#124 115 and observat\* study                   
                                                   \#125 115 and rand\* clin\* trial                
                                                   \#126 115 and control\* study                    
                                                   \#127 115 and rand\* study                       
                                                   **\#128 116--127**                               

Data extraction
---------------

Titles and abstracts of all retrieved references were scanned by one author (BvS), after which two reviewers (BvS and TvdW) independently assessed the remaining set of articles for definitive inclusion or exclusion. The final set of included studies was assessed by one of the authors (BvS) on the basis of the following methodological aspects; study design, type of intervention, participants (profession), setting (location of care and country), and methods (unit of allocation and quality criteria); his findings were checked by another author (TvdW). The final decisions on inclusion and data extraction per study were made by consensus.

Data analysis
-------------

The examination of the methodological quality of the studies was guided by the Data Collection Template (July 2002) of The Cochrane Effective Practice and Organisation of Care (EPOC) group, see [www.epoc.uottawa.ca/tools.htm](www.epoc.uottawa.ca/tools.htm).

Results
=======

Over 1800 titles and abstracts were scanned, and the full text of 37 articles was assessed. Ten of these articles (2 articles reporting on the same study) met our inclusion criteria, resulting in 9 studies being included. The included studies were categorized according to their main type of intervention(s) in EPOC terms. These are summarized in [Table 3A](#tbl3A){ref-type="table"}-[C](#tbl3C){ref-type="table"}.

###### 

Empirical studies on stimulation of actual and appropriate use of cardiovascular risk tables in normal practice, characteristics, and effects. Studies using one (or more) professional strategies without patient involvement

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author:, year:\                                             Methods: [a](#tf3a-1){ref-type="table-fn"}\   Type of intervention:\                                                                      Main outcome(s):\                                                                                             Results:
  Setting: location of care, country\                         Quality criteria for RCTs:\                   Professional\                                                                               a) health professional outcome(s)\                                                                            
  Participants: profession\                                   Study period                                  Financial Organizational\                                                                   b) patient outcome(s)                                                                                         
  Patients (N)\                                                                                             Regulatory                                                                                                                                                                                                
  Study design:                                                                                                                                                                                                                                                                                                       
  ----------------------------------------------------------- --------------------------------------------- ---------------------------------------------------------------------------- -------------- ------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                            **Intervention group**                                                       **Controls**                                                                                                                 

  [@b27]\                                                     UA: general practice\                         Professional:\                                                               usual care     a\) recording CV risk factors\                                                                                a\) no differences between the groups\
  General Practice, Norway\                                   US: patient level\                            - distrib.educat. materials\                                                                b) blood pressure, cardiovascular risk score, serum cholesterol, and weight (or BMI)                          b) I: sign. mean reduction in diastolic blood pressure (1mm Hg.) compared to C (p = 0.05), no differences between the groups in choles-terol, BMI, or CV risk\
  General practitioners, assistants\                          Quality criteria: 1 ? 2 no\                   -educat. telephone calls\                                                                                                                                                                                 \*CDSS was applied for 104 patients (12%) only
  Patients, N = 2239\                                         18 months                                     -educat. meeting (90 min.)\                                                                                                                                                                               
  RCT                                                                                                       -stand-alone CDSS including risk score                                                                                                                                                                    

  [@b35], [@b33]\                                             UA: general practice\                         Professional:\                                                               usual care     a\) ability to identify patients at high risk (5-year cardiovascular risk ≥ 10%) compared to gold standard\   a\) no differences in terms of patients identified as being at high risk\
  General practice, UK\                                       US: professionals, patients\                  -stand-alone CDSS including training plus paper version of the risk chart\                  a) prescribing of cardiovascular drugs\                                                                       a) moderate agreement between professionals' risk assessment and 'gold standard' (κ = 0.49 at baseline and 0.56 at 12 mths.)\
  General practitioners (n = 74), practice nurses (n = 11)\   Quality criteria:\                            or:\                                                                                        b) cardiovascular risk reduction                                                                              a) increased prescribing of CV drugs in the chart-only grp. compared to usual care and CDSS group (p = 0.007)\
  Patients, N = 614\                                          1 yes 2 ?\                                    -paper version of the risk chart only                                                                                                                                                                     b) no differences between I and C
  RCT (3-arms)                                                12 months\                                                                                                                                                                                                                                              
                                                              \*multi-level analysis                                                                                                                                                                                                                                  

  [@b5]\                                                      UA: CME-group\                                Professional:\                                                               \-             a\) actual use of the risk assessment tool                                                                    a\) I: use of risk assessment tool I: 76% compared to C: 52% (p = 0.003)
  General practice, Belgium\                                  US: GPs\                                      - educat. meeting                                                                                                                                                                                         
  CME-groups of GPs\                                          Quality criteria:\                                                                                                                                                                                                                                      
  GPs, N = 343 Randomized trial                               1 no 2 ?\                                                                                                                                                                                                                                               
                                                              16 months                                                                                                                                                                                                                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Methods: UA = unit of allocation, US = unit of analysis, Quality criteria for RCTs: 1 concealed allocation, 2 blinded assessment of primary outcome(s).

###### 

Empirical studies on stimulation of actual and appropriate use of cardiovascular risk tables in normal practice, characteristics, and effects. Studies combining professional- and patient-mediated strategies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author:, year:\                              Methods: [a](#tf3b-1){ref-type="table-fn"}\   Type of intervention:\                                                   Main outcome(s):\                                                                   Results:
  Setting: location of care, country\          Quality criteria for RCTs:\                   Professional\                                                            a) health professional outcome(s)\                                                  
  Participants: profession\                    Study period                                  Financial\                                                               b) patient outcome(s)                                                               
  Patients (N)\                                                                              Organizational\                                                                                                                                              
  Study design:                                                                              Regulatory                                                                                                                                                   
  -------------------------------------------- --------------------------------------------- ----------------------------------------- ------------------------------ ----------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
                                                                                             **Intervention group**                    **Controls**                                                                                                       

  Fretheim, 2006\                              UA: general practice\                         Professional:\                            -short telephone interview     a\) CV risk assessed before prescribing anti-hypertensive or lipid-lowering drugs   a\) no changes in CV risk assessment
  General practice, Norway\                    US: patients\                                 -elec. risk calculator\                                                                                                                                      
  General practitioners\                       Quality criteria: 1 yes 2 yes 12 months\      - stand-alone CDSS\                                                                                                                                          
  GPs, N =501 Cluster randomized controlled\   \*multi-level analysis                        - (computerized) reminders\                                                                                                                                  
  Trial                                                                                      -educat. outreach visits by pharmacist\                                                                                                                      
                                                                                             -audit and feedback\                                                                                                                                         
                                                                                             *Patient*:\                                                                                                                                                  
                                                                                             -printed educat. materials                                                                                                                                   

  [@b49]\                                      UA: GPs\                                      Professional:\                            -distrib. educat. materials\   a\) appropriate risk classification, risk assessment, and risk management           a\) no signifi cant differences in GPs'performance regarding risk classifi cation, assessment, and management
  General practice,\                           US: patients\                                 -distrib. of educat. materials\           -educat. meeting                                                                                                   
  The Netherlands\                             Quality criteria: 1 yes 2 no 6 months\        -educat. meeting (4 hrs.)\                                                                                                                                   
  General practitioners (N = 34)\              \*multi-level analysis                        *Patient*:\                                                                                                                                                  
  Patients, N = 623\                                                                         -decision aid including the risk chart                                                                                                                       
  Cluster randomized trial                                                                                                                                                                                                                                
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Methods: UA = unit of allocation, US = unit of analysis, Quality criteria for RCTs: 1 concealed allocation, 2 blinded assessment of primary outcome(s).

###### 

Empirical studies on stimulation of actual and appropriate use of cardiovascular risk tables in normal practice, characteristics, and effects. Studies using/combining professionaland organization strategies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author:, year:\                                   Methods: [a](#tf3c-1){ref-type="table-fn"}\   Type of intervention:\                                                                                              Main outcome(s):\                                                                                          Results:
  Setting: location of care, country\               Quality criteria for RCTs:\                   Professional\                                                                                                       a) health professional outcome(s)\                                                                         
  Participants: profession\                         Study period                                  Financial\                                                                                                          b) patient outcome(s)                                                                                      
  Patients (N)\                                                                                   Organizational Regulatory                                                                                                                                                                                                      
  Study design:                                                                                                                                                                                                                                                                                                                  
  ------------------------------------------------- --------------------------------------------- ---------------------------------------------------------------------- -------------------------------------------- ---------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
                                                                                                  **Intervention group**                                                 **Controls**                                                                                                                                            

  [@b15]\                                           UA: GP\                                       Org., structural:\                                                     n/a                                          a\) start of lipid-lowering drugs                                                                          a\) improved statin prescription after CHD risk assessment\
  General Practice, UK\                             US: patients\                                 -risk calculation facility embedded in lipid test ordering procedure                                                                                                                                                           \*a minority of general practices (N = 14) used the service; requested CHD risk assessment
  General Practitioners\                            Quality criteria: n/a\                                                                                                                                                                                                                                                       
  Patients, N -- 999 Non-controlled study           1 - 2 -12 months                                                                                                                                                                                                                                                             

  [@b26]\                                           UA: patients\                                 Org., structural:\                                                     usual care                                   a\) diabetes treatment, prescribing antihypertensive and lipid-lowering drugs, and referral to dietician   a\) all patients\
  Hospital outpatient clinic, UK Medical doctors\   US: patients\                                 -calculated CVD risk indicated on patients' file                                                                                                                                                                               -no changes in prescribing, referral, or number of interventions\
  Patients, N = 323\                                Quality criteria:\                                                                                                                                                                                                                                                           a) high-risk group (\> 20% five year risk)\
  RCT                                               1 yes 2 ? Duration ?                                                                                                                                                                                                                                                         -I: increased prescribing of anti-hypertensive and lipid-lowering drugs compared to C (p = 0.01).

  [@b30]\                                           UA: patients\                                 Professional:\                                                         detailed educational form without CVD-risk   a\) statin prescriptions for high-risk patients                                                            a\) no differences in statin prescribing in high-risk group, I: 40%, C: 38%
  Hospital outpatient clinics, USA\                 US: patients\                                 - educat. meeting Org., structural:\                                                                                                                                                                                           
  Physicians N=164\                                 Quality criteria: 1 yes\                      -calculated CVD risk indicated on patient file (external reviewers)                                                                                                                                                            
  Patients, N= 368\                                 2 ?\                                                                                                                                                                                                                                                                         
  RCT                                               5 months                                                                                                                                                                                                                                                                     

  [@b40]\                                           UA: patients\                                 Professional:\                                                         n/a                                          a\) 5-year CV-risk assessment recorded                                                                     a\) CV risk assessment increased from 4.7% up to 53.5% one year after implementation of the system change\
  Primary Care, New Zealand\                        US: patients\                                 -electronic or paper-based risk calculator\                                                                                                                                                                                    \*screening rates were higher in practices where nurses led the screening
  Primary Practice Team, GPs and nurses\            Quality criteria: n/a\                        -(computerized) reminders for screening\                                                                                                                                                                                       
  Patients, N = 6570\                               1 -- 2 --\                                    -CDSS for management Org., structural:\                                                                                                                                                                                        
  Noncontr. before and after design                 12 months                                     -letter to patient with invitation for risk assessment by nurse                                                                                                                                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Methods: UA = unit of allocation, US = unit of analysis, Quality criteria for RCTs: 1 concealed allocation, 2 blinded assessment of primary outcome(s).

Participants and setting
------------------------

Nearly all participants in the included studies were medical doctors, either general practitioners or internal medicine residents, while 3 studies involved practice nurses or practice assistants in the implementation strategy. The location of care included hospital outpatient clinics in the UK and the USA ([@b26]; [@b30]) and GP surgeries in Norway, the UK, the Netherlands, and New Zealand ([@b27]; [@b35]; [@b33]; [@b17]; [@b40]; [@b49]).

Characteristics of the studies
------------------------------

The trials differed considerably in size: the smallest trial included 323 patients, while a bigger trial included 2239 patients. In this large study, however, the risk table was only applied to 12% (N = 104) of the eligible patients ([@b28]). In the majority of the studies, the proportion of patients who completed the proposed study protocol was small. One trial included no patients, but 343 GPs were asked to evaluate the intervention strategy ([@b6]). This trial, as well as 5 other studies, may have suffered from a unit of allocation problem, particularly, a difference between the unit of allocation and the unit of analysis, without controlling for this by means of clustered data analysis.

Seven randomized controlled trials (RCT) were found, one of them a prospective RCT without follow-up ([@b26]), the others varying in time until follow-up assessment from 6 to 18 months ([@b27]; [@b33]; [@b30]; [@b17]). One study reported on blinded assessment of the primary outcomes ([@b17]), while 5 studies mentioned concealment of intervention allocation. Primary outcomes relating to the health professionals were the recording of CV risk and risk factors, the ability to identify patients at high risk, and appropriate indications for treatment (prescribing of cardiovascular drugs). Secondary, patient-related outcomes concerned CV risk and risk reduction, blood pressure, serum cholesterol, body mass index, and self-reported lifestyle.

Type of intervention and effects
--------------------------------

We found that the interventions in the included studies were basically limited to three types: professional strategies or combinations of them (without patient involvement); combinations of professional- and patient-mediated strategies; organizational strategies or combinations of professional and organizational strategies. In general, the effects of the interventions on primary outcomes were small, absent or contradictory for the same outcome.

### Professional strategies

Education was the single intervention in one of the three 'professional-oriented' trials. This was found to significantly increase the use of the risk tables ([@b6]). The other two studies involved one or more educational meetings for transfer of knowledge, in combination with training in the use of a stand-alone computerized decision support system (CDSS) ([@b27]; [@b33]). In the 3-armed trial by Montgomery, the use of the CDSS plus a paper version of the risk tables, or a paper version only versus usual care, had no effect on the ability to identify patients at high cardiovascular risk or on more accurate use of the risk tables. Although increased prescribing of CV drugs and a significantly lower systolic blood pressure was seen in the 'risk chart only' group, no differences in risk reduction were found compared to usual care ([@b35]; [@b33]). Interventions in which the educational meetings and the use of a CDSS were supplemented with educational materials, follow-up telephone calls and feedback on actual performance had no effect on the recording of risk factors, cholesterol level, BMI, or CV risk. However, a significant mean reduction in diastolic blood pressure (1 mm HG) was reported ([@b27]).

### Professional- and patient-mediated strategies

Two trials combined professional interventions, such as education plus audit and feedback, with a patient-mediated intervention, involving new information on patients' CV risk being made available at the consultation ([@b17]), and introducing a decision aid for patients ([@b49]). The trial by [@b17] used an outreach visit to educate GPs on CV prevention and risk communication, as well as to give feedback on actual performance, and train them to use a CDSS. The CDSS generated 'pop-ups' on screen whenever an elevated blood pressure or cholesterol level was recorded, had a CV-risk calculator, generated treatment advice, and could be used to print patient-education materials. It had no effect on CV-risk assessment prior to prescribing ([@b17]). The trial by [@b49] used a combination of a 4-hour training session in the use of the risk tables, risk communication, and a decision aid for patients, which was to be used in two consultations to ensure patient involvement in the second consultation. Neither resulted in improved performance of the GPs in terms of risk classification, assessment, or management ([@b49]).

### Organizational

The focus of the interventions in this group of 4 studies (2 of which were noncontrolled) was a change in facilities and equipment. In one of the two controlled trials, patients' CV risk was clearly indicated (by the researcher) on the front page of the patients' file. This had no effect on prescribing behavior, treatment or referral, except that a significant increase in the use of CV drugs was observed for the high-risk group ([@b26]). The other controlled trial involved adding an educational meeting of the professionals, and contrasted a low-detail educational form including CV risk on the patients' file in the intervention group with a more detailed form without CV risk in the control group. This resulted in overuse of statins in the moderate-risk group and no effect in the high-risk group ([@b30]).

One of the two noncontrolled studies evaluated a risk-calculating facility embedded in a lipid test ordering procedure. Statin prescribing was found to be improved after risk assessment, but only 14 GPs used the laboratory service involved in the study ([@b15]). The other study used a CDSS with risk calculator, integrated in the practice management system, which linked pop-up alerts to pre-selected files that appeared whenever the patient file was opened. In addition, the eligible patients were sent a letter explaining the value of screening for CV risk and inviting them for a risk assessment. CV-risk assessment had increased from 4.7% to 53.5% one year after implementation of the system change. Screening rates were higher in practices where nurses were responsible for the screening.

Discussion
==========

The small number of studies that could be included in this systematic review shows that the development of effective strategies for the implementation of cardiovascular risk tables in primary prevention has been sparsely studied so far, and that our understanding of ways to speed up the uptake of such new tools remains limited. The most common type of strategy was organizational, involving methods like presenting CV risk on the front page of patients' files or as a laboratory facility, and pro-active screening by pop-up alerts on the computer screen with invitations sent to patients' homes for risk assessment. Patient-mediated implementation strategies have hardly been studied. Although no clear relation between a particular type of strategy and the success or failure of implementation was observed, promising strategies seemed to be those involving teamwork, nurse-led clinics and integrated IT support.

This review used a sensitive search, with language restricted to Dutch, English, and German publications. Although a restriction to randomized controlled trials is often desirable in systematic literature reviews, as it yields studies with the highest level of evidence, we chose to include non-controlled and quasi-controlled intervention studies as well, because of the expected low number.

Most of the studies we found do not seem to be theory-driven or problem-driven (ie, tailored to barriers and facilitators), although in two studies, the strategy was guided by a systematic survey of barriers and facilitators before implementation was started ([@b17]; [@b49]). Despite this, no effects were found in these studies. Apart from a qualitative process evaluation, there is a need for more in-depth qualitative methods, eg, in-depth interviews or focus groups with health professionals, to increase our understanding of this lack of effect ([@b16]). Ideally, this should be done along the lines of established planning models for implementation processes. It seems that insufficient attention has been given to the various phases in the process of change for care providers and teams (Grol and [@b20]; [@b24]).

Although the theories and models on organizational determinants of innovation of care processes overlap, and the empirical evidence behind their assumptions about human behavior or organizational change is limited, we tried to apply our findings to some of the many available theories. The Theory on Innovative Organizations tells us to take the type of organization into account. Decentralized decision making about innovations is crucial and good teamwork is one of the main keys for successful change. Process Reengineering Theory advises to focus on multidisciplinary care processes and collaboration instead of individual decision making. The theory aims to analyze and redesign the work process related to CVD prevention. The lessons learnt from this review, such as task delegation to a practice nurse and sending invitational letters to patients for screening, could be part of it. Theories on Organizational Culture stress that changes in the culture can stimulate changes in performance; more teamwork, flexibility and external orientation. Organizational Learning Theory advises to create conditions within the (practice) organization for continuous learning at all levels ([@b25]).

Although financial incentives are an effective way of changing professional behavior, none of the studies we found used a financial incentive for the implementation of risk tables. It might be a powerful strategy, since most professionals might in the near future encounter financial incentives that are linked to the quality of care, as is already customary in the UK. Many indicators of the Quality and Outcomes Framework are related to prevention of CVD. It appears that significant health gains could result from achieving these quality targets ([@b32]; [@b37]; [@b42]; [@b2]).

Ideally, implementation strategies should be tailored to support physicians' needs, and as such should be based on the problems they are actually facing ([@b23]; [@b24]). We distinguished 5 needs related to CVD prevention, and propose recommendations for implementation based on the review:

1.  Supporting physicians in the process of case-finding of potential high-risk patients. This is an essential step in successful application of the risk tables. Active support can be provided by pop-up alerts linked to pre-selected files that appear whenever a patient file is opened. Letters sent to patients' homes, explaining the value of screening for CV risk and with an invitation for risk assessment, can further improve screening rates, especially in those practices with an established culture of practice-nurse led clinics and teamwork between the practice nurses and the GPs.

2.  Supporting physicians in completing the risk profile. A CDSS proved to be effective only when the decision support system was integrated in the practice management system.

3.  Supporting physicians in calculating the risk. Most of the studies promoted the use of a risk table, either paper-based or computerized, for risk calculation. The main problem seemed to be the actual use of the risk calculation tools, which many of the physicians failed to do. Initially, it was suggested that risk tables would be useful for clinicians to help them master concepts relating to CHD prevention, ie, as a kind of educational tool rather than a practice instrument for risk calculation and management ([@b29]). Since nurses are likely to be the future consumers ([@b51]), GPs could be supported by nurses in this task. Presenting the actual risk to the GPs, eg, by indicating the risk on the front page of patients' files, only had a minor effect on physicians' behavior in terms of prescribing CV drugs. Nevertheless, confronting GPs with their patients' actual risk may have corrected their misperceptions and could as such help to generate a better performance, as misperception of cardiovascular risk is not uncommon among health professionals ([@b35]; [@b5]; [@b18]; [@b34]; [@b19]; [@b47]).

4.  Supporting physicians in risk communication. Once the risk has been calculated the next challenge is how to present it in an effective way. Most patients have a hard time understanding CVD risks ([@b13]; [@b48]). Perception of risks tends to be inaccurate and people find it difficult to handle risks ([@b12]). The format (framing) in which risk information is presented affects people's perception of risks and decision-making ([@b44]). For example, framing in relative risk or loss framing are more persuasive compared to framing in absolute risk or gain framing respectively. This is reported for doctors ([@b36]), and patients ([@b10]; [@b14]; [@b31]). Risk communication should include weighing up of risks and benefits of a treatment choice, and address the patient's perception of probability of an event as well as the value of the event for that individual ([@b10]). To achieve this, health professionals need training to increase their competences in risk communication.

5.  Supporting physicians in deciding, jointly with the patient, on appropriate action for management. The use of a computerized decision support system to help physicians decide on appropriate management may result in some small favorable effects on prescribing behavior and blood pressure. So far, involving patients in the decision on appropriate management with the help of educational materials (including the risk table) has had no effect. Although patient involvement seems to be an effective prevention strategy, it is still unclear how this can be achieved ([@b9]; [@b11]). A successful strategy might be to delegate this task to a nurse or health coach, who has more time to explain CV risk and for patient involvement in decisions on management and follow-up ([@b46]; [@b41]; [@b8]). Such a strategy is a subject of research in the current IMPALA trial (ISRCTN51556722), in which a risk communication tool and a decision aid are issued to patients for preparation at home, and in which the practice nurse applies an adapted motivational interviewing technique to discuss the risk and options for risk reduction (see [www.trialregister.nl](www.trialregister.nl)).

Conclusion
==========

Effective primary prevention of cardiovascular diseases is not easy, and research on effective strategies for the implementation of risk tables has been sparse. Nevertheless, good teamwork, nurse-led clinics, and smart software programs, integrated in the practice management system, seem to be promising strategies for patient selection and risk assessment. Achieving patient involvement, a precondition for successful CV-risk management, is a challenge for future research that, together with the development of other professional- and organization-implementation strategies, needs to be embedded in the methodology of implementation science.
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